Drug Profile


Alternative Names: CI 1011

Latest Information Update: 28 Oct 2003

Price : $50

At a glance

  • Originator Pfizer
  • Class Antihyperlipidaemics
  • Mechanism of Action Sterol O-acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Hyperlipidaemia

Most Recent Events

  • 28 Oct 2003 Discontinued - Phase-III for Hyperlipidaemia in USA (PO)
  • 28 Oct 2003 Discontinued - Phase-III for Atherosclerosis in USA (PO)
  • 04 Aug 2003 A clinical study has been added to the adverse events and Hyperlipidaemia pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top